608 related articles for article (PubMed ID: 22877506)
1. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.
Wandt H; Schaefer-Eckart K; Wendelin K; Pilz B; Wilhelm M; Thalheimer M; Mahlknecht U; Ho A; Schaich M; Kramer M; Kaufmann M; Leimer L; Schwerdtfeger R; Conradi R; Dölken G; Klenner A; Hänel M; Herbst R; Junghanss C; Ehninger G;
Lancet; 2012 Oct; 380(9850):1309-16. PubMed ID: 22877506
[TBL] [Abstract][Full Text] [Related]
2. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.
Desborough M; Estcourt LJ; Doree C; Trivella M; Hopewell S; Stanworth SJ; Murphy MF
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010982. PubMed ID: 27548292
[TBL] [Abstract][Full Text] [Related]
3. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
Estcourt LJ; Stanworth S; Doree C; Trivella M; Hopewell S; Blanco P; Murphy MF
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010984. PubMed ID: 26505729
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
[TBL] [Abstract][Full Text] [Related]
5. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
Crighton GL; Estcourt LJ; Wood EM; Trivella M; Doree C; Stanworth S
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010981. PubMed ID: 26422767
[TBL] [Abstract][Full Text] [Related]
6. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
Rebulla P; Finazzi G; Marangoni F; Avvisati G; Gugliotta L; Tognoni G; Barbui T; Mandelli F; Sirchia G
N Engl J Med; 1997 Dec; 337(26):1870-5. PubMed ID: 9407153
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
Bornhäuser M; Kienast J; Trenschel R; Burchert A; Hegenbart U; Stadler M; Baurmann H; Schäfer-Eckart K; Holler E; Kröger N; Schmid C; Einsele H; Kiehl MG; Hiddemann W; Schwerdtfeger R; Buchholz S; Dreger P; Neubauer A; Berdel WE; Ehninger G; Beelen DW; Schetelig J; Stelljes M
Lancet Oncol; 2012 Oct; 13(10):1035-44. PubMed ID: 22959335
[TBL] [Abstract][Full Text] [Related]
8. A no-prophylaxis platelet-transfusion strategy for hematologic cancers.
Stanworth SJ; Estcourt LJ; Powter G; Kahan BC; Dyer C; Choo L; Bakrania L; Llewelyn C; Littlewood T; Soutar R; Norfolk D; Copplestone A; Smith N; Kerr P; Jones G; Raj K; Westerman DA; Szer J; Jackson N; Bardy PG; Plews D; Lyons S; Bielby L; Wood EM; Murphy MF;
N Engl J Med; 2013 May; 368(19):1771-80. PubMed ID: 23656642
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial.
Lye DC; Archuleta S; Syed-Omar SF; Low JG; Oh HM; Wei Y; Fisher D; Ponnampalavanar SSL; Wijaya L; Lee LK; Ooi EE; Kamarulzaman A; Lum LC; Tambyah PA; Leo YS
Lancet; 2017 Apr; 389(10079):1611-1618. PubMed ID: 28283286
[TBL] [Abstract][Full Text] [Related]
10. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation.
Wandt H; Schaefer-Eckart K; Frank M; Birkmann J; Wilhelm M
Bone Marrow Transplant; 2006 Feb; 37(4):387-92. PubMed ID: 16400342
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study.
Tay J; Allan D; Beattie S; Bredeson C; Fergusson D; Maze D; Sabloff M; Thavorn K; Tinmouth A
BMJ Open; 2016 Oct; 6(10):e013483. PubMed ID: 27798034
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation.
Stanworth SJ; Hyde C; Heddle N; Rebulla P; Brunskill S; Murphy MF
Cochrane Database Syst Rev; 2004 Oct; (4):CD004269. PubMed ID: 15495093
[TBL] [Abstract][Full Text] [Related]
16. An audit of platelet transfusion within the Wellington Cancer Centre.
Buhrkuhl DC; Karlsson MK; Carter JM
Intern Med J; 2012 Jan; 42(1):65-70. PubMed ID: 21040321
[TBL] [Abstract][Full Text] [Related]
17. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 x 10(9) and 20 x 10(9) per L.
Nevo S; Fuller AK; Hartley E; Borinsky ME; Vogelsang GB
Transfusion; 2007 May; 47(5):801-12. PubMed ID: 17465944
[TBL] [Abstract][Full Text] [Related]
18. Dose of prophylactic platelet transfusions and prevention of hemorrhage.
Slichter SJ; Kaufman RM; Assmann SF; McCullough J; Triulzi DJ; Strauss RG; Gernsheimer TB; Ness PM; Brecher ME; Josephson CD; Konkle BA; Woodson RD; Ortel TL; Hillyer CD; Skerrett DL; McCrae KR; Sloan SR; Uhl L; George JN; Aquino VM; Manno CS; McFarland JG; Hess JR; Leissinger C; Granger S
N Engl J Med; 2010 Feb; 362(7):600-13. PubMed ID: 20164484
[TBL] [Abstract][Full Text] [Related]
19. New strategies for the optimal use of platelet transfusions.
Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
[TBL] [Abstract][Full Text] [Related]
20. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
